GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 2.489 M

Revenue: As of FY2025 Q2, the actual value is USD 2.489 M.

EPS: As of FY2025 Q2, the actual value is USD -0.79.

Segment Revenue

• Revenue from Government Contract: $852,282 for the three months ended June 30, 2025, compared to $300,677 for the same period in 2024. For the six months ended June 30, 2025, revenue was $2,489,145, compared to $300,677 for the same period in 2024.

Operational Metrics

• Net Loss: - $5,369,783 for the three months ended June 30, 2025, compared to - $5,064,042 for the same period in 2024. For the six months ended June 30, 2025, net loss was - $10,727,434, compared to - $10,914,174 for the same period in 2024.
• Research and Development Expenses: $4,728,998 for the three months ended June 30, 2025, compared to $4,276,868 for the same period in 2024. For the six months ended June 30, 2025, expenses were $10,083,586, compared to $8,702,596 for the same period in 2024.
• General and Administrative Expenses: $1,542,190 for the three months ended June 30, 2025, compared to $1,086,030 for the same period in 2024. For the six months ended June 30, 2025, expenses were $3,229,635, compared to $2,543,383 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $10,300,078 for the six months ended June 30, 2025, compared to - $7,624,778 for the same period in 2024.
• Net Cash Used in Investing Activities: - $27,612 for the six months ended June 30, 2025, compared to $0 for the same period in 2024.
• Net Cash Provided by Financing Activities: $7,914,611 for the six months ended June 30, 2025, compared to $2,733,901 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: GeoVax plans to advance its product candidates through human clinical trials and pursue regulatory approval and commercialization via internal development or external licensing and partnerships. The company is focused on progressing its lead programs, including the GEO-CM04S1 COVID-19 vaccine, Gedeptin® for solid tumor cancers, and GEO-MVA for Mpox and smallpox.
• Non-Core Business: GeoVax is also developing additional vaccine candidates targeting filoviruses (Ebola Zaire, Ebola Sudan, and Marburg) and Zika virus, as well as potential applications of the GEO-MVA and Gedeptin platforms in broader infectious disease and oncology indications.
• Priority: The company aims to secure additional capital resources through public or private equity or debt financings, government grants/contracts, arrangements with strategic partners, or other sources to continue its planned operations into the fourth quarter of 2025.